Edition:
United Kingdom

Acasti Pharma Inc (ACST.OQ)

ACST.OQ on NASDAQ Stock Exchange Capital Market

1.60USD
11 Dec 2017
Change (% chg)

$0.04 (+2.56%)
Prev Close
$1.56
Open
$1.55
Day's High
$1.63
Day's Low
$1.55
Volume
33,181
Avg. Vol
75,086
52-wk High
$3.34
52-wk Low
$1.11

Latest Key Developments (Source: Significant Developments)

Acasti Pharma grants Chinese pharma co exclusive license to commercialize CaPre in China​
Wednesday, 22 Nov 2017 

Nov 22 (Reuters) - Acasti Pharma Inc :Acasti Pharma Inc - ‍clarifies term of proposed strategic partnership with China pharmaceutical company​.Acasti - Under proposed term, Chinese pharmaceutical co to be granted exclusive license to commercialize CaPre in certain Asian countries including China​.  Full Article

Acasti Pharma ‍enters into non-binding agreement with China-based pharma
Monday, 20 Nov 2017 

Nov 20 (Reuters) - Acasti Pharma Inc :Acasti Pharma Inc - ‍entered into a non-binding term sheet with a China-based pharmaceutical company​.Acasti Pharma - ‍if definitive agreement is reached, signed, term sheet contemplates co would receive an upfront payment of us$8 million upon signing.Acasti Pharma Inc - ‍if definitive agreement is reached & signed, co would also receive potential additional milestone payments in excess of $125 million​.  Full Article

Acasti Pharma says is offering 11.7 mln common shares‍​
Thursday, 16 Nov 2017 

Nov 16 (Reuters) - Acasti Pharma Inc :Says it is offering 11.7 million common shares‍​ - SEC Filing.  Full Article

Acasti Pharma reports Q2 loss per share C‍$0.31​
Monday, 13 Nov 2017 

Nov 13 (Reuters) - Acasti Pharma Inc :Acasti Pharma reports second quarter FY 2018 financial results.Acasti Pharma Inc qtrly loss per share C‍$0.31​.  Full Article

Acasti Pharma Q2 loss per share $0.22
Tuesday, 11 Oct 2016 

Acasti Pharma Inc : reports second quarter 2017 financial results . Qtrly loss per share $0.22 . if co does not raise additional funds, there exists uncertainty that casts substantial doubt about ability to continue as going concern .Management has reasonable expectation that corporation will be able to raise additional funds.  Full Article

Acasti posts qtrly loss per share of $0.29
Monday, 11 Jul 2016 

Acasti Pharma Inc: Acasti announces first quarter results .Qtrly loss per share $0.29.  Full Article

Acasti Pharma says Jan D'Alvise named as CEO
Thursday, 12 May 2016 

Acasti Pharma Inc : Says Jan D'Alvise appointed as president and chief executive officer effective June 1, 2016 .Jan D'Alvise appointed president & CEO of Acasti Pharma.  Full Article

Acasti Pharma Inc says appointment of Roderick Carter, as Executive Chairman of the Board
Tuesday, 1 Mar 2016 

Acasti Pharma Inc:Says appointment of Roderick Carter, as Executive Chairman of the Board.  Full Article

BRIEF-Acasti Pharma grants Chinese pharma co exclusive license to commercialize CaPre in China​

* Acasti Pharma Inc - ‍clarifies term of proposed strategic partnership with China pharmaceutical company​